Collegium Pharmaceutical, Inc. completed the acquisition of Ironshore Therapeutics in September 2024, marking a strategic expansion into the neurology market with the addition of Jornay PM. This move diversifies Collegium's portfolio beyond its established pain management business. The acquisition is expected to establish Jornay PM as a lead growth driver for the company.
Jornay PM, a treatment for Attention-Deficit Hyperactivity Disorder (ADHD), is anticipated to deliver pro forma net revenue in excess of $100 million in 2024. This immediate accretion from Jornay PM underscores the financial strength of Collegium. The company is committed to the seamless integration of Ironshore and maximizing the value of Jornay PM.
This acquisition represents Collegium's first step toward building another therapeutic area of focus, leveraging its commercial expertise. The company expects to generate record revenue in 2025, driven by growth in its pain portfolio and the addition of Jornay PM.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.